Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea
Open Access
- 1 March 2019
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 34 (2), 409-417
- https://doi.org/10.3904/kjim.2016.418
Abstract
Background/Aims: Little is known about tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity in human immunodeficiency virus (HIV)-infected patients in Korea. The objective of this study was to evaluate the incidence and risk factors of TDF-associated nephrotoxicity among HIV-infected patients in Korea. Methods: A single-center retrospective cohort study was conducted on HIV-infected patients in Korea. We included patients who had started TDF or abacavir (ABC)-based antiretroviral therapy (ART) between October 2006 and December 2014. Estimated glomerular filtration rate (eGFR) was estimated using the Chronic Kidney Disease-Epidemiology Collaboration equation. Renal dysfunction was defined as > 25% decrease of baseline eGFR. A propensity matched case-control study was conducted to compare renal dysfunction rates between the two groups. The risk factors of nephrotoxicity were analyzed by Cox regression analysis. Results: A total of 210 HIV-infected patients were included in the study, of which, 108 were TDF-based ART group and 102 were ABC-based ART group. Renal dysfunction occurred in 16 patients (14.8%) in the TDF group and 11 (10.8%) in the ABC group. Incidence of renal dysfunction of TDF and ABC group was 9.66 per 100 person-years (PYs) and 5.14 per 100 PYs, respectively (p = 0.176). In propensityscore-matched analysis, renal dysfunction rates were TDF 13.3% versus ABC 13.3% (p > 0.999). In multivariable analysis, Centers for Disease Control and Prevention clinical category C was a significant risk factor for renal dysfunction. Conclusions: Approximately, 13% of HIV-infected patients treated with TDF had renal dysfunction. Advanced stage of HIV infection was a significant risk factor for renal dysfunction.Keywords
Funding Information
- Pusan National University
This publication has 18 references indexed in Scilit:
- Comorbidities as risk factors of chronic kidney disease in HIV-infected personsPostępy Higieny I Medycyny Doświadczalnej, 2015
- Nephrotoxicity during tenofovir treatment: a three-year follow-up study in a Brazilian reference clinicThe Brazilian Journal of Infectious Diseases, 2015
- Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse EventsPLOS ONE, 2013
- Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV InfectionPLOS ONE, 2012
- Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients: A Retrospective Cohort Study of Japanese PatientsPLOS ONE, 2011
- Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathyKidney International, 2010
- Bone Pain Due to Fractures Revealing Osteomalacia Related to Tenofovir-Induced Proximal Renal Tubular Dysfunction in a Human Immunodeficiency Virus-Infected PatientJCR: Journal of Clinical Rheumatology, 2009
- Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/RitonavirJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug InteractionsClinical Infectious Diseases, 2006
- Tenofovir‐Related Nephrotoxicity in Human Immunodeficiency Virus–Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes InsipidusClinical Infectious Diseases, 2003